Related references
Note: Only part of the references are listed.Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study
Anne Segolene Cottereau et al.
BLOOD (2018)
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma
Mathieu Nessim Toledano et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Sally F. Barrington et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas
Faycal Ben Bouallegue et al.
MEDICAL PHYSICS (2017)
PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma
Liangjun Rao et al.
MEDICINE (2016)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants
Mixue Xie et al.
MEDICAL ONCOLOGY (2015)
False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review
Anastasia Chalkidou et al.
PLOS ONE (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients
Michel Meignan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
Myriam Sasanelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prognostic Value of Metabolic Tumor Volume Estimated by 18F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease
Jihyun Kim et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement
Moo-Kon Song et al.
ANNALS OF HEMATOLOGY (2012)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Christian Recher et al.
LANCET (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate
Nicolas Rachinel et al.
Current Hematologic Malignancy Reports (2009)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
H Tilly et al.
BLOOD (2003)
The role of the host-tumor interface and cell hybridization in invasive cancer
A Bukovsky et al.
MEDICAL HYPOTHESES (2001)
Share Paper
